Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
Description mAb targeting interleuking-23 (IL-23)
Molecular Target Interleukin-23 (IL-23)
Mechanism of ActionInterleukin-23 (IL-23) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today